Eagle IP is excited to sponsor and participate in IAM’s IPBC Connect, returning to Zoom for a week of high-level discussions involving the world’s leading IP experts. From 22-26 March, IAM hosted more than 20 individual interactive digital sessions, each designed to facilitate the exchange of information and insight, benchmarking and the sharing of the best practice in key areas of strategic IP value creation.

Our VP Jennifer Che spoke as an IP expert at an open discussion forum about Patent Law Update Asia, happening March 23 at 11AM HKT (March 22, 11PM EST for those in North America).

You can register for as many sessions as you like across the week, building your own schedule. Find out more here: httpss://cvent.me/VnkWam?RefId=Sponsor

我們過去活動

Recommended Insights

Breaking: China Released New Implementation Measures for the New Patent Linkage System

2021年7月14日
On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]

CHINA: New Patent Examination Guidelines Now Available for Public Comment

2021年8月4日
Two months after the new Chinese Patent law came into effect, the CNIPA has released a new set of Patent Examination Guidelines (proposed version) for public comments on Aug 3, 2021. Here are the explanation of the amendments (Chinese only). Here is the full set of proposed amendments (Chinese only). Briefly, the new amendment focuses […]

Introducing the New USPTO Cancer Moonshot Expedited Examination Pilot Program

2023年1月10日
Starting from February 1, 2023, the USPTO will begin the new Cancer Moonshot Expedited Examination Pilot Program that advances out-of-turn applications that are directed to oncology or smoking cessation. This new program will replace the Cancer Immunotherapy Pilot Program that has been in place since 2016, and covers more technologies than only cancer immunotherapies. Applications […]

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
Top crossarrow-right